Page 1

inflaRx • • • • • InflaRx Reports First Quarter 2021 Financial & Operating Results Severe COVID - 19 trial enrollment reaches 178 patients ; interim analysis expected in Q3 At the FDA's suggestion , planning to request a Type A meeting to further discuss primary endpoint for the Phase III clinical development of vilobelimab in Hidradenitis Suppurativa Vilobelimab proved safe and well tolerated as add - on therapy to standard of care in US ANCA - associated vasculitis safety trial Completed target enrollment in Phase Ila Pyoderma Gangraenosum trial Cash , cash equivalents and financial assets of approximately € 137.8 million as of March 31 , 2021 Jena , Germany , May 12 , 2021 - InflaRx ( Nasdaq : IFRX ) , a clinical - stage biopharmaceutical company developing anti - inflammatory therapeutics by targeting the complement system , announced today financial results for the three months ended March 31 , 2021 . " We have made significant progress with our vilobelimab clinical programs in the first few months of 2021 , " said Prof. Niels C. Riedemann , Chief Executive Officer and Founder of InflaRx . " The team has worked tirelessly to progress the enrollment of our severe COVID - 19 trial and we now expect the interim analysis to occur in the third quarter of this year . Despite the increase in vaccinations , patients remain in urgent need of better treatments for severe COVID - 19 . For HS , following feedback on the Special Protocol Assessment , we plan to continue our discussions with the FDA about the design of our Phase III trial in a Type A meeting . Following the positive safety data from our US ANCA - associated vasculitis trial , we are looking forward to data readouts in our European AAV trial by the end of the year . In our Pyoderma Gangraenosum trial we have reached target enrollment and expect additional data readouts in 2021. " Recent Highlights and R & D Update Issuance of Common Shares and Warrants On February 25 , 2021 , the Company sold an aggregate of 15,000,000 common shares through a public offering . The common shares were sold at a price of $ 5.00 per share . For each common share purchased , an investor also received a warrant to purchase a common share